DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Pipamperone is an investigational drug.
There have been 4 clinical trials for Pipamperone. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Disease, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are PharmaNeuroBoost N.V., Hannover Medical School, and [disabled in preview].
There is one US patent protecting this investigational drug and sixteen international patents.
Recent Clinical Trials for Pipamperone
|Pharmacovigilance in Gerontopsychiatric Patients||Hannover Medical School||Phase 3|
|POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia||PharmaNeuroBoost N.V.||Phase 2|
|Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)||PharmaNeuroBoost N.V.||Phase 3|
Top disease conditions for Pipamperone
Top clinical trial sponsors for Pipamperone
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pipamperone||Start Trial||Quinolone-based compounds, formulations, and uses thereof||University of South Florida (Tampa, FL) Northeastern University (Boston, MA)||Start Trial|
|Pipamperone||Start Trial||Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors||Bristol-Myers Squibb Company (Princeton, NJ)||Start Trial|
|Pipamperone||Start Trial||Compositions and methods for treating Dengue virus infection||The J. David Gladstone Institutes (San Francisco, CA) The Regents of the University of California (Oakland, CA)||Start Trial|
|Pipamperone||Start Trial||Compounds useful for the treatment of metabolic disorders and synthesis of the same||North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)||Start Trial|
|Pipamperone||Start Trial||Multivalent ligands targeting VEGFR||The Methodist Hospital System (Houston, TX)||Start Trial|
|Pipamperone||Start Trial||4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists||Bristol-Myers Squibb Company (Princeton, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pipamperone||European Patent Office||2766345||2031-10-14||Start Trial|
|Pipamperone||European Patent Office||2899183||2031-10-14||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|